SlideShare a Scribd company logo
1 of 25
Download to read offline
1
Innovative Therapeutics For Respiratory Health
Investor Presentation
1Q-2021
2
Forward Looking Statement
These forward-looking statements relate to future events or future financial performance of the
Company. All such forward-looking statements involve risks and uncertainties and are not guaranties
of future performance. An investment in the securities of Aridis is speculative in nature, involves a
high degree of risk, and should not be made by an investor who cannot bear the economic risk of its
investment for an indefinite period of time and who cannot afford the loss of its entire investment.
These include many important factors that affect our ability to achieve our stated objectives including,
but not limited to:
* The timing of regulatory submissions;
* Our ability to obtain and maintain regulatory approval of our existing product candidates and any
other product candidates we may develop, and the labeling under any approval we may obtain;
* Approvals for clinical trials may be delayed or withheld by regulatory agencies;
* Pre-clinical and clinical studies will not be successful or confirm earlier results or meet expecta-
tions or meet regulatory requirements or meet performance thresholds for commercial success;
* The timing and costs of clinical trials, the timing and costs of other expenses;
* Our ability to obtain funding from third parties;
* Management and employee operations and execution risks;
* Loss of key personnel;
* Competition;
* Market acceptance of products;
* Intellectual property risks;
* Assumptions regarding the size of the available market, benefits of our products, product pricing,
timing of product launches;
* The uncertainty of future financial results;
* Risks associated with this offering;
* Our ability to attract collaborators and partners;
* Our reliance on third party organizations.
We operate in a very competitive and rapidly changing environment. New risks emerge from time to
time. It is not possible for our management to predict all risks, nor can we assess the impact of all
factors on our business or the extent to which any factor, or combination of factors, may cause actual
results to differ materially from those contained in any forward-looking statements we may make. In
light of these risks, uncertainties and assumptions, the forward-looking events and circumstances
discussed in this presentation may not occur and actual results could differ materially and adversely
from those anticipated or implied in the forward-looking statements.
Except as required by law, neither we nor any other person assumes responsibility for the accuracy
and completeness of the forward-looking statements. We undertake no obligation to update publicly
any forward-looking statements for any reason after the date of this presentation to conform these
statements to actual results or to changes in our expectations.
We have filed a registration statement (including a prospectus) with the Securities and Exchange
Commission ("SEC") for the offering to which this communication relates. Before you invest, you
should read the prospectus in the registration statement and other documents we have filed with the
SEC for more complete information about us and this offering. You may get these documents for free
by visiting EDGAR on the SEC web site at http://www.sec.gov. Alternatively, we, any underwriter, or
any dealer participating in the offering will arrange to send you the prospectus if you request it from
Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor, New York, NY
10022; email: prospectus@cantor.com. This presentation shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.
3
Targets IND
Pre-Clinical
Products Phase 2
Phase 1 Phase 3
Gram (+) Bacteria
S. aureus a-toxin
Pneumonia & Blood Stream Infections
HAP/VAP
Cystic Fibrosis
COVID-19
Gram (-) Bacteria
P. aeruginosa LPS O11
Gram (-) & (+)
Iron Acquisition Systems
COVID-19
AR-301 mAb
(Salvecin)
AR-101 mAb
(Aerumab)
AR-501
(Panaecin)
AR-712 mAb
AR-701
Bacteremia
A. baumannii
AR-401 mAb
Product Pipeline
Next
Milestone
Interim Futility
data 2H2021
Phase 2/3
tbd
Phase 2a data
2H2021
Phase 1/2
2H2021
IND
4Q2022
Gram (-) Bacteria
RBD mAb
4
Antibiotics
mAb
Monoclonal
Antibody (mAb)
Bacteria
Toxins
Virus
Using Human Monoclonal Antibody for Infections
5
3
0
Months
6 9 12 15 18 21 24 27
TRADITIONAL: Discovery, Development, and Manufacturing
APEX TM
Discovery, Development, and Manuf. 12-15 months time saving
Convalescent
COVID-19 patient
B-cell
Selected
Cloned CDRs
or H&L of IgG’s
APEX TM
Nanoarrays
B-cell
repertoire screening
B.R.E.A.T.H. TM
CHO cell line
CRISPR
Guided Integration
GMP
Manufacturing
λPEX Monoclonal Antibody Discovery and
Production Platform Technology
6
Kyaw MH et al., 2015 BMC Health Serv Res. 15:241
Restrepo (2010) ICHE 31:509-515
Hospital Days
7.2
60 days
40 days
20 days
$220,000
$110,000
Control Staph Pseudomonas Control Staph Pseudomonas
37.9
55.4
$33,851
$146,978
$213,104
In-Patient Costs
ICU stay
All Cause
Mortality
1.1 day 6.9 days 14.8 days
3% 16% 20%
1.1 day 6.9 days 14.8 days
3% 16% 20%
~252,000 ICU patients
US claims database (2018)
n=201 n=394
Healthcare Burden: S. aureus and P. aeruginosa Bacteria
Hospital 44.4%
%
0
.
1
2
y
c
a
m
r
a
h
P
%
3
.
6
1
y
r
o
t
a
r
o
b
a
L
Respiratory Treatment (Mech. ventilation) 9.3%
Radiology (+CT Scans) 3.3%
%
9
.
1
y
g
o
l
o
i
d
r
a
C
Operating Room 1.4%
Diagnostics (Blood ECG) 1.9%
Pulmonary Diagnostic 0.4%
%
3
.
0
c
i
d
a
e
p
o
h
t
r
O
Survey of 30 cases (median)
7
Normal Alveolus
PMN
Macrophages
α-toxins
α-toxins
Staphylococcus aureus
Staphylococcus aureus
Targets S. aureus α-Toxin
Necrosis
Alveolar
air space
Type 1 cells
Interstitium
Anti-toxin monoclonal
antibody approach is a
proven MOA, e.g.
Anthrax mAb Raxibacumab (GSK-EBSI)
S. Aureus mAb MEDI4893 (AZN)
Intact
Immune Cell
Gram (+) bacteria: S. aureus
mAb
α-toxins attacking
immune cell
Red blood cells
Neutrophils
Macrophages, Monocytes
Toxins 2013, 5(6), 1140-1166
T-cells
Pneumoncytes
Endothelial cells
AR-301 Mechanism of Action:
Host cells killed by α-toxins
Commercialized
Under development
8
Antibiotics-alone Adjunct therapy
Standard
of Care
Standard
of Care
AR-301
Superiority Trial Design
VS.
With positive data, provides for value-based premium reimbursement
Therapeutic Treatment in Acute Pneumonia Setting
9
Randomized, double-blind, placebo-controlled, single ascending dose of AR-301
31 sites across EU and U.S.
SOC [antibiotics alone] + Placebo n=16
SOC + AR-301 (1 mg/kg ) n= 6
SOC + AR-301 (3 mg/kg) n= 8
SOC + AR-301 (10 mg/kg) n=10
SOC + AR-301 (20 mg/kg) n= 8
48 patients with HAP or VAP caused by S. aureus
Safety and pharmacokinetics
Data trend in favor of adjunctive treatment benefit
Time to removal of ventilator (VAP patients)
Microbiological cure
Shorter time to eradication
Days in ICU
Design
Patient Selection
Groups
Primary Endpoint
Secondary Endpoint Hospitalization days
All-cause mortality
Clinical cure rate
AR-301 Phase 2: Trial Recently Completed
10
Antibiotic
Half Life
20 mg/kg
(hours) Time since start of infusion
50% (half-life mark)
Mean
Plasma
Concentration
24 48 72 96 120 144 168
0
ug/mL
200
ug/mL
400
ug/mL
600
ug/mL
Adjunctive AR-301 treated groups were well
antibiotics alone (placebo) group (n=48).
Few adverse events (AEs) deemed related to
AR-301 (2.8%).
No serious adverse events (SAEs) related to
AR-301.
Deaths were deemed unrelated to AR-301
treatment (n=6).
(plasma half-life of 23-31 days)
AR-301
AR-301: Favorable Phase 2 Safety & PK Data
11
Probability
of
Receiving
Mechanical
Ventilation
Days on Mechanical Ventilators
+AR-301 Pooled (n=20)
Antibiotics alone (n=5)
5 10 15 20 25
100%
80%
60%
40% 40%
50%
improvement
20%
Probability
of
Receiving
Mechanical
Ventilation
0
Francois, B. et al. 2018 Intensive Care Medicine.
Aggregated AR-301 treated VAP groups
exhibited lower probability of requiring
mechanical ventilation vs. placebo.
Phase 2
12
1-to-1 randomized,
double-blind,
placebo-controlled, single
dose IV infusion
Enrolling 240 patients with
VAP caused by S. aureus
across 125 sites in 20
countries (U.S., EU, Asia)
Evaluating the potential of
adjunctive AR-301 (20 mg/kg)
to SOC antibiotics vs.
antibiotics alone
Primary endpoint of clinical
cure rate at day 21
Interim futility analysis of 120 patients
readout in 1H2022
Test of
Clinical
Cure
Randomize
& Treat
infusion
AR-301 at 20 mg/kg
IV infusion
n = 120
Day 21
n = 120
Broad
spectrum
antibiotics
Broad
spectrum
antibiotics
(ClinicalTrials.gov ID NCT03027609)
AR-301 Phase 3: Trial Design
in 2H2021 and final data
13
Powering Calculation and Assumptions
n = 240 enrollment target
over-powered to achieve
superior clinical cure rate
p<0.05
** Rationale for 20% absolute
clinical cure rate improvement setting
Considered clinically meaningful to physicians
Ph2a data showed trend toward improvements in
shorter ventilation time & microbiological eradication
(i.e. 2 of the 3 components of the primary endpoint)
AR-301 Phase 3 Study
Study
Power
80%
90%
75%
75%
95%
95%
20%
20%
n = 55
n = 69
n = 110
n = 138
Control
(SOC)*
AR-301
+ SOC
Absolute
**
Evaluable
per group
Total
Enrolled
Primary Endpoint: Clinical Cure Rate
14
Sources
Potential S. aureus HAP/VAP Patients by Market
395,000 Patients in the US, Japan, EU
Gram (+) Staphylococcus aureus-Induced HAP/VAP
Lifecycle opportunities include surgical site, skin/skin structure, UTI, and BSI infections due to S. aureus
Estimated $6 billion annual healthcare cost burden attributable to
S. aureus nosocomial pneumonia
Breakdown
of Strains 48%
52%
1 DR/Decision Resources, LLC. 2016;
2 Chastre J, and Fagon J-Y, Ventilator-associated pneumonia, State
of the Art, Am J Respir Critical Care Med, 2002 (165): 867-903.
3 Warren DK, Outcome and Attributable Cost of VAP among ICU
patients in a suburban medical center,
Critical Care Med 2003;31(5):1312-7.
MRSA
MSSA
90,000
251,600
U.S.A.
Japan
53,700
Europe
$6 Billion Market for (AR-301): VAP, HAP
15
SOC antibiotics in HAP/VAP:
Avycaz / ceftazidime/avibactam (AstraZeneca): $13,764 (14 days course)
Vibativ/ Telavancin (Astellas): $8,841 (21 days course)
Pneumonia caused by MRSA
$1,000
AR-301 Product Contribution
Key Assumptions
First-line adjunctive treatment
MRSA only HAP / VAP / HCAP
60% marketshare
US / EU / Japan
$10,500 per course
$Million
(Net
of
Expenses)
$800
$600
$400
$200
$00
2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034
1st Phase 3 2nd Phase 3 BLA & Launch
16
AR-301
Pre-Emptive Treatment In S. Aureus Colonized Patients Also Show Evidence
of Clinical Benefits
At-risk (non-infected)
Asymptomatic
Lung colonized, High risk
Asymptomatic
Decreased risk of VAP 32%
Decreased risk of VAP 47% (<65 yrs old)
Full-on lung infection
Ventilator-assoc. pneumonia
Prophylactic
AstraZeneca’s
Suvratoxumab
Pre-emptive
Phase 2 Results (n=196)*:
[data 1H2022]
Phase 3 (n = 240)
Treatment for Acute
AR-301 Data: Proxy Data from AZN’s Suvratoxumab
17
AR-501: Novel Inhaled Non-Antibiotic
Mechanism of Action
Small Molecule Anti-infective
Iron (Fe) is necessary for bacterial metabolic
functions. AR-501 (gallium, Ga) replaces Fe
AR-501 impairs mulitple bacterial functions
Standard antibiotics inhibit single targets
Ga
Gallium
18
PARI eFlow
nebulizer
AR-501 Phase 1/2: Healthy & Cystic Fibrosis Patients
Phase 1 Healthy Volunteers
(1H-2019) Single Ascending Dose
6 mg
18 patients 6 patients
20 mg
AR-501
Done
AR-501
Placebo
18 patients 6 patients
Placebo
40 mg
6 mg 20 mg 40 mg
(1H-2020) Multiple Ascending Doses
t = 0, 1, 2, 3, 4 weeks
Done AR-501
30 patients 15 patients
Placebo
6 mg 20 mg 40 mg
(2H-2021) Multiple Ascending Doses
t = 0, 1, 2 weeks
Phase 2 Cystic Fibrosis Patients
Primary Endpoint:
Safety and PK
Secondary Endpoints:
Lung function of CF patients
(changes in FEV1)
Sputum bacteriology
Data Readout:
Phase 2a CF subjects in 2H2021
CF Foundation Funded
Ph1 study results: AR-501 was well tolerated
19
Sputum
concentration
mg/mL
300
IV
Inhaled
(est.)
2
Gallium
Gallium
Placebo
Placebo
1
10%
8%
6%
4%
2%
0%
-2%
-4%
-6%
6 14 28 56
60 60 58 60 59
59 57 57 56 56
Day Days Days Days Days
Patients Patients Patients Patients Patients
Mean
Relative
Change
from
Baseline
FEV
(L)
Intent to Treat Population CF Patients
Inhaled
Delivery
A single IV dose of gallium resulted in statistical
significant improvement in lung infection
Data from University of Washington: Goss, C. et al. 2018
N. Am. Cystic Fibrosis Conference Abstract #307 (*estimate based on animal PK data)
Safety & Efficacy
of IV Gallium
Demonstrated
Proxy Data:
20
*UK, So. Africa, Brazil, Japan SARS-CoV-2 strains
AR-712 two mAbs cocktail bind to COVID’s
spike protein, blocking COVID & its
variants* from being able to bind
to the host cell.
AR-712: Inhaled COVID-19 mAb Program
Highly potent SARS-CoV-2 fully human mAbs from convalescent COVID-19 patients
- Proprietary stable inhaled formulation designed for direct lung delivery
- Therapeutically eradicated SARS-CoV-2 at ultra low dose (~0.05 mg/kg) in
animal challenge model
- Up to year-long protection (engineered for plasma half-life extension)
- Engineered removal of antibody disease enhancement (ADE) risk
AR-712
LLY (CoV555)
REGN (10933/10987)
>1,000x
2 - 6 mg (est)
700 to 7,500 mg
2,400 to 8,000 mg
AR-712 in-human dosing is the lowest vs. all competitors*
*Scaling to human dose based on animal SARS-CoV-2 challenge study. See https://www.biorxiv.org/content/10.1101/2020.10.14.339150v1
21
AR-712: Inhaled COVID-19 mAb Program
Convenient self-dosing in-home
Target Populations
- Designed to lower the barrier to COVID-19 treatment in outpatients
- Treatment mild to moderate COVID-19 non-hospitalized patients
- Prophylaxis [elderly, high risk frontline workers, etc]
Phase 1/2 in 2H21
Phase 3 data in 2022
https://www.biorxiv.org/content/10.1101/2020.10.14.339150v1.
22
AR-301
AR-101
AR-501
AR-712
Phase 3
Interim Futility
Phase 2a
Full Data
Phase 2b
Full Data
Ph1/2
Phase 2/3
T.B.D.
Phase 3
Full Data
2021 2022
Key Milestones
Toxin Blocker
Immune Modulation
Cystic Fibrosis
COVID-19
IND
Enabling
Ph3
23
Vu Truong
CEO, Director
(Formerly Medimmune, Aviron)
Michael Nazak
Chief Financial Officer
(Formerly Coherus, intekrin)
Steve Chamow
VP, Development
(Formerly Genentech, Abgenix)
Hasan Jafri
Chief Medical Officer
(Formerly AstraZeneca/Medimmune)
Elizabeth Leininger
VP, Regulatory
(Formerly FDA, Novartis)
Mitch Rosner
VP, Quality
(Formerly Synthetic Gen., IDEC)
Lynne Deans
VP, Clinical Operations
(Formerly Roche, Dermira)
Senior Management
24
Eric Patzer, Ph.D.
Director, Chairman
(Co-Founder, Aridis)
Robert Ruffolo, Ph.D., D.Sc.
Director
(Former President Wyeth/Pfizer)
Craig Gibbs, Ph.D., M.B.A.
Director
(Commercial Gilead; Genentech)
John Hamilton, M.B.A.
Director
(CFO, Depomed; BioMarin)
Susan Windham-Bannister, Ph.D.
Director
(Assoc. Women in STEM, Mass. Life Sci. Ctr)
Vu Truong, Ph.D.
Director
(CEO, Aridis)
Board of Directors
25
Financial Information
Condensed Consolidated Statement of Operations
Three Months
Ended
09/30/2020
($ in 000’s)
Total revenue $1,000
Research and development $4,161
General and administrative $1,631
Loss from operations $(5,792)
Net loss $(5,786)
Balance Sheet
As of
Sept. 30, 2020
Cash and cash equivalents (excludes ~$8.5m Oct. 2020) $6,212
Common stock:
100,000,000 shares authorized;
8,923,374 shares issued and outstanding as of September 30th, 2020
Analyst Coverage ($18 - $22 PT)
- Cantor Fitzgerald (Louise Chen)
- HC Wainwright (Vernon Bernadino)
- ROTH Capital (Jonathan Aschoff)
- Maxim Group (Jason MacCarthy)
- Northland Securities (Carl Byrnes)
- Laidlaw (Frank Brisebois)

More Related Content

What's hot

Genetic Technologies Investor Presentation March 2021
Genetic Technologies Investor Presentation March 2021Genetic Technologies Investor Presentation March 2021
Genetic Technologies Investor Presentation March 2021RedChip Companies, Inc.
 
G Medical Innovations Investor Presentation September 2021
G Medical Innovations Investor Presentation September 2021G Medical Innovations Investor Presentation September 2021
G Medical Innovations Investor Presentation September 2021RedChip Companies, Inc.
 
2016 shareholder meeting presentation final
2016 shareholder meeting presentation final2016 shareholder meeting presentation final
2016 shareholder meeting presentation finalGalenabio
 
Safety Data Exchange Agreements (Brief)
Safety Data Exchange Agreements (Brief)Safety Data Exchange Agreements (Brief)
Safety Data Exchange Agreements (Brief)Arete-Zoe, LLC
 
Oncology Product Highlight - Boehringer Ingelheim's Tovok & Vargatef
Oncology Product Highlight -  Boehringer Ingelheim's Tovok & VargatefOncology Product Highlight -  Boehringer Ingelheim's Tovok & Vargatef
Oncology Product Highlight - Boehringer Ingelheim's Tovok & VargatefWill Roettger
 
Eua authorization letter for LYHER Covid-19 IgG/IgM Antibody rapid Test Kits
Eua authorization letter for LYHER Covid-19 IgG/IgM Antibody rapid Test KitsEua authorization letter for LYHER Covid-19 IgG/IgM Antibody rapid Test Kits
Eua authorization letter for LYHER Covid-19 IgG/IgM Antibody rapid Test KitsHK HuZef
 
GXP Inspection readiness
GXP Inspection readinessGXP Inspection readiness
GXP Inspection readinessArete-Zoe, LLC
 
Corporate Deck - AACR 2020
Corporate Deck - AACR 2020Corporate Deck - AACR 2020
Corporate Deck - AACR 2020AsaElmore
 
Virios Therapeutics Investor Deck March 2021
Virios Therapeutics Investor Deck March 2021Virios Therapeutics Investor Deck March 2021
Virios Therapeutics Investor Deck March 2021RedChip Companies, Inc.
 
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...ANGLE plc
 
Immunetics, inc. product pipeline analysis
Immunetics, inc.   product pipeline analysisImmunetics, inc.   product pipeline analysis
Immunetics, inc. product pipeline analysisAarkstore Enterprise
 
Avastin & Erbitux Launch in in CRC - Key Learnings and Implications (061704)
Avastin & Erbitux Launch in in CRC - Key Learnings and Implications (061704)Avastin & Erbitux Launch in in CRC - Key Learnings and Implications (061704)
Avastin & Erbitux Launch in in CRC - Key Learnings and Implications (061704)Will Roettger
 
Dossier on drug safety
Dossier on drug safetyDossier on drug safety
Dossier on drug safetyLanre Suleiman
 
HR Compliance & Insurance Benefit Perspectives: What Employers Should Be Awar...
HR Compliance & Insurance Benefit Perspectives: What Employers Should Be Awar...HR Compliance & Insurance Benefit Perspectives: What Employers Should Be Awar...
HR Compliance & Insurance Benefit Perspectives: What Employers Should Be Awar...Rea & Associates
 

What's hot (19)

Genetic Technologies Investor Presentation March 2021
Genetic Technologies Investor Presentation March 2021Genetic Technologies Investor Presentation March 2021
Genetic Technologies Investor Presentation March 2021
 
TLSA Investor Presentation October 2021
TLSA Investor Presentation October 2021TLSA Investor Presentation October 2021
TLSA Investor Presentation October 2021
 
G Medical Innovations Investor Presentation September 2021
G Medical Innovations Investor Presentation September 2021G Medical Innovations Investor Presentation September 2021
G Medical Innovations Investor Presentation September 2021
 
2016 shareholder meeting presentation final
2016 shareholder meeting presentation final2016 shareholder meeting presentation final
2016 shareholder meeting presentation final
 
Safety Data Exchange Agreements (Brief)
Safety Data Exchange Agreements (Brief)Safety Data Exchange Agreements (Brief)
Safety Data Exchange Agreements (Brief)
 
Oncology Product Highlight - Boehringer Ingelheim's Tovok & Vargatef
Oncology Product Highlight -  Boehringer Ingelheim's Tovok & VargatefOncology Product Highlight -  Boehringer Ingelheim's Tovok & Vargatef
Oncology Product Highlight - Boehringer Ingelheim's Tovok & Vargatef
 
Eua authorization letter for LYHER Covid-19 IgG/IgM Antibody rapid Test Kits
Eua authorization letter for LYHER Covid-19 IgG/IgM Antibody rapid Test KitsEua authorization letter for LYHER Covid-19 IgG/IgM Antibody rapid Test Kits
Eua authorization letter for LYHER Covid-19 IgG/IgM Antibody rapid Test Kits
 
GXP Inspection readiness
GXP Inspection readinessGXP Inspection readiness
GXP Inspection readiness
 
Corporate Deck - AACR 2020
Corporate Deck - AACR 2020Corporate Deck - AACR 2020
Corporate Deck - AACR 2020
 
Catasys Presentation
Catasys Presentation Catasys Presentation
Catasys Presentation
 
Virios Therapeutics Investor Deck March 2021
Virios Therapeutics Investor Deck March 2021Virios Therapeutics Investor Deck March 2021
Virios Therapeutics Investor Deck March 2021
 
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...
 
Data exclusivity
Data exclusivityData exclusivity
Data exclusivity
 
Immuron Presentation
Immuron PresentationImmuron Presentation
Immuron Presentation
 
Immunetics, inc. product pipeline analysis
Immunetics, inc.   product pipeline analysisImmunetics, inc.   product pipeline analysis
Immunetics, inc. product pipeline analysis
 
Avastin & Erbitux Launch in in CRC - Key Learnings and Implications (061704)
Avastin & Erbitux Launch in in CRC - Key Learnings and Implications (061704)Avastin & Erbitux Launch in in CRC - Key Learnings and Implications (061704)
Avastin & Erbitux Launch in in CRC - Key Learnings and Implications (061704)
 
Dossier on drug safety
Dossier on drug safetyDossier on drug safety
Dossier on drug safety
 
Therapix March 2017 Final
Therapix March 2017 FinalTherapix March 2017 Final
Therapix March 2017 Final
 
HR Compliance & Insurance Benefit Perspectives: What Employers Should Be Awar...
HR Compliance & Insurance Benefit Perspectives: What Employers Should Be Awar...HR Compliance & Insurance Benefit Perspectives: What Employers Should Be Awar...
HR Compliance & Insurance Benefit Perspectives: What Employers Should Be Awar...
 

Similar to Aridis Investor Presentation 2021

Aridis Pharmaceuticals Investor Presentation
Aridis Pharmaceuticals Investor PresentationAridis Pharmaceuticals Investor Presentation
Aridis Pharmaceuticals Investor PresentationRedChip Companies, Inc.
 
Roth Capital Partners' 28th Annual Roth Conference
Roth Capital Partners' 28th Annual Roth ConferenceRoth Capital Partners' 28th Annual Roth Conference
Roth Capital Partners' 28th Annual Roth ConferenceExact Sciences
 
Interpace Diagnostics Investor Presentation
Interpace Diagnostics Investor PresentationInterpace Diagnostics Investor Presentation
Interpace Diagnostics Investor PresentationRedChip Companies, Inc.
 
DRUG SAFETY REPORTING.pptx
DRUG SAFETY REPORTING.pptxDRUG SAFETY REPORTING.pptx
DRUG SAFETY REPORTING.pptxAmeena Kadar
 
1706 ir deck full w_appendix v1_cmd_v12_nett
1706 ir deck full w_appendix v1_cmd_v12_nett1706 ir deck full w_appendix v1_cmd_v12_nett
1706 ir deck full w_appendix v1_cmd_v12_netttargovax2017
 
Can-Fite BioPharma - Investor Presentation June 2020
Can-Fite BioPharma - Investor Presentation June 2020Can-Fite BioPharma - Investor Presentation June 2020
Can-Fite BioPharma - Investor Presentation June 2020RedChip Companies, Inc.
 
LTRN Investor Presentation- January 2021
LTRN Investor Presentation- January 2021LTRN Investor Presentation- January 2021
LTRN Investor Presentation- January 2021RedChip Companies, Inc.
 
Public Device & Biopharma Ophthalmology Company Showcase - Adverum Biotechnol...
Public Device & Biopharma Ophthalmology Company Showcase - Adverum Biotechnol...Public Device & Biopharma Ophthalmology Company Showcase - Adverum Biotechnol...
Public Device & Biopharma Ophthalmology Company Showcase - Adverum Biotechnol...Healthegy
 
Virios Therapeutics Presentation Q3 2021
Virios Therapeutics Presentation Q3 2021Virios Therapeutics Presentation Q3 2021
Virios Therapeutics Presentation Q3 2021RedChip Companies, Inc.
 
1706 ir deck full w_appendix v1_cmd_v6_uten appendix
1706 ir deck full w_appendix v1_cmd_v6_uten appendix1706 ir deck full w_appendix v1_cmd_v6_uten appendix
1706 ir deck full w_appendix v1_cmd_v6_uten appendixtargovax2017
 
Exact Sciences Baird 2015 Healthcare Conference Presentation
Exact Sciences Baird 2015 Healthcare Conference PresentationExact Sciences Baird 2015 Healthcare Conference Presentation
Exact Sciences Baird 2015 Healthcare Conference PresentationExact Sciences
 
2016/10 – IR call – Dupilumab
2016/10 – IR call – Dupilumab2016/10 – IR call – Dupilumab
2016/10 – IR call – DupilumabSanofi
 
Cowen's 35th Annual Healthcare Conference Presentation
Cowen's 35th Annual Healthcare Conference PresentationCowen's 35th Annual Healthcare Conference Presentation
Cowen's 35th Annual Healthcare Conference PresentationExact Sciences
 

Similar to Aridis Investor Presentation 2021 (20)

Aridis Pharmaceuticals Investor Presentation
Aridis Pharmaceuticals Investor PresentationAridis Pharmaceuticals Investor Presentation
Aridis Pharmaceuticals Investor Presentation
 
Aridis Investor Presentation 2022 Q1
Aridis Investor Presentation 2022 Q1Aridis Investor Presentation 2022 Q1
Aridis Investor Presentation 2022 Q1
 
ARDS Presentation
ARDS PresentationARDS Presentation
ARDS Presentation
 
Roth Capital Partners' 28th Annual Roth Conference
Roth Capital Partners' 28th Annual Roth ConferenceRoth Capital Partners' 28th Annual Roth Conference
Roth Capital Partners' 28th Annual Roth Conference
 
Interpace Diagnostics Investor Presentation
Interpace Diagnostics Investor PresentationInterpace Diagnostics Investor Presentation
Interpace Diagnostics Investor Presentation
 
DRUG SAFETY REPORTING.pptx
DRUG SAFETY REPORTING.pptxDRUG SAFETY REPORTING.pptx
DRUG SAFETY REPORTING.pptx
 
Investor Present 04202017
Investor Present  04202017Investor Present  04202017
Investor Present 04202017
 
1706 ir deck full w_appendix v1_cmd_v12_nett
1706 ir deck full w_appendix v1_cmd_v12_nett1706 ir deck full w_appendix v1_cmd_v12_nett
1706 ir deck full w_appendix v1_cmd_v12_nett
 
Can-Fite BioPharma - Investor Presentation June 2020
Can-Fite BioPharma - Investor Presentation June 2020Can-Fite BioPharma - Investor Presentation June 2020
Can-Fite BioPharma - Investor Presentation June 2020
 
LTRN Investor Presentation- January 2021
LTRN Investor Presentation- January 2021LTRN Investor Presentation- January 2021
LTRN Investor Presentation- January 2021
 
Public Device & Biopharma Ophthalmology Company Showcase - Adverum Biotechnol...
Public Device & Biopharma Ophthalmology Company Showcase - Adverum Biotechnol...Public Device & Biopharma Ophthalmology Company Showcase - Adverum Biotechnol...
Public Device & Biopharma Ophthalmology Company Showcase - Adverum Biotechnol...
 
Virios Therapeutics Presentation Q3 2021
Virios Therapeutics Presentation Q3 2021Virios Therapeutics Presentation Q3 2021
Virios Therapeutics Presentation Q3 2021
 
Soligenix Corporate Presentation
Soligenix Corporate PresentationSoligenix Corporate Presentation
Soligenix Corporate Presentation
 
1706 ir deck full w_appendix v1_cmd_v6_uten appendix
1706 ir deck full w_appendix v1_cmd_v6_uten appendix1706 ir deck full w_appendix v1_cmd_v6_uten appendix
1706 ir deck full w_appendix v1_cmd_v6_uten appendix
 
IDXG Investor Presentation
IDXG Investor PresentationIDXG Investor Presentation
IDXG Investor Presentation
 
Investor Present 04202017
Investor Present 04202017Investor Present 04202017
Investor Present 04202017
 
Virios Therapeutics Investor 2021
Virios Therapeutics Investor 2021Virios Therapeutics Investor 2021
Virios Therapeutics Investor 2021
 
Exact Sciences Baird 2015 Healthcare Conference Presentation
Exact Sciences Baird 2015 Healthcare Conference PresentationExact Sciences Baird 2015 Healthcare Conference Presentation
Exact Sciences Baird 2015 Healthcare Conference Presentation
 
2016/10 – IR call – Dupilumab
2016/10 – IR call – Dupilumab2016/10 – IR call – Dupilumab
2016/10 – IR call – Dupilumab
 
Cowen's 35th Annual Healthcare Conference Presentation
Cowen's 35th Annual Healthcare Conference PresentationCowen's 35th Annual Healthcare Conference Presentation
Cowen's 35th Annual Healthcare Conference Presentation
 

More from RedChip Companies, Inc.

DGLY Corporate Investor Relations Deck Oct 2023
DGLY Corporate Investor Relations Deck Oct 2023DGLY Corporate Investor Relations Deck Oct 2023
DGLY Corporate Investor Relations Deck Oct 2023RedChip Companies, Inc.
 
Lantern Pharma Investor Presentation Oct 2023
Lantern Pharma Investor Presentation Oct 2023Lantern Pharma Investor Presentation Oct 2023
Lantern Pharma Investor Presentation Oct 2023RedChip Companies, Inc.
 
Aditxt, Inc. (NASDAQ: ADTX) Presentation
Aditxt, Inc. (NASDAQ: ADTX) PresentationAditxt, Inc. (NASDAQ: ADTX) Presentation
Aditxt, Inc. (NASDAQ: ADTX) PresentationRedChip Companies, Inc.
 
1847 Holdings Corporate Presentation 1847 Holdings March 2023
1847 Holdings Corporate Presentation 1847 Holdings March 20231847 Holdings Corporate Presentation 1847 Holdings March 2023
1847 Holdings Corporate Presentation 1847 Holdings March 2023RedChip Companies, Inc.
 
Sharps Investor Presentation October 2023
Sharps  Investor Presentation October 2023Sharps  Investor Presentation October 2023
Sharps Investor Presentation October 2023RedChip Companies, Inc.
 
GENE Investor Presentation Genetic Technologies August 2023
GENE Investor Presentation Genetic Technologies August 2023GENE Investor Presentation Genetic Technologies August 2023
GENE Investor Presentation Genetic Technologies August 2023RedChip Companies, Inc.
 
Splash Beverage Investor Presentation June 2023
Splash Beverage Investor Presentation June 2023Splash Beverage Investor Presentation June 2023
Splash Beverage Investor Presentation June 2023RedChip Companies, Inc.
 

More from RedChip Companies, Inc. (20)

ZOM Investor Presentations Oct 2023
ZOM Investor Presentations Oct 2023ZOM Investor Presentations Oct 2023
ZOM Investor Presentations Oct 2023
 
Docola Presentation
Docola PresentationDocola Presentation
Docola Presentation
 
INNO Holdings Presentation
INNO Holdings PresentationINNO Holdings Presentation
INNO Holdings Presentation
 
EBI IR Presentation Sep 2023
EBI IR Presentation Sep 2023EBI IR Presentation Sep 2023
EBI IR Presentation Sep 2023
 
ASPI Investor Deck Oct 2023
ASPI Investor Deck Oct 2023ASPI Investor Deck Oct 2023
ASPI Investor Deck Oct 2023
 
MDNA Investor Presentation May 2023
MDNA Investor Presentation May 2023MDNA Investor Presentation May 2023
MDNA Investor Presentation May 2023
 
DGLY Corporate Investor Relations Deck Oct 2023
DGLY Corporate Investor Relations Deck Oct 2023DGLY Corporate Investor Relations Deck Oct 2023
DGLY Corporate Investor Relations Deck Oct 2023
 
Lantern Pharma Investor Presentation Oct 2023
Lantern Pharma Investor Presentation Oct 2023Lantern Pharma Investor Presentation Oct 2023
Lantern Pharma Investor Presentation Oct 2023
 
Sharps Investor Deck Oct 2023
Sharps Investor Deck Oct 2023 Sharps Investor Deck Oct 2023
Sharps Investor Deck Oct 2023
 
Aditxt, Inc. (NASDAQ: ADTX) Presentation
Aditxt, Inc. (NASDAQ: ADTX) PresentationAditxt, Inc. (NASDAQ: ADTX) Presentation
Aditxt, Inc. (NASDAQ: ADTX) Presentation
 
1847 Holdings Corporate Presentation 1847 Holdings March 2023
1847 Holdings Corporate Presentation 1847 Holdings March 20231847 Holdings Corporate Presentation 1847 Holdings March 2023
1847 Holdings Corporate Presentation 1847 Holdings March 2023
 
Sharps Investor Presentation October 2023
Sharps  Investor Presentation October 2023Sharps  Investor Presentation October 2023
Sharps Investor Presentation October 2023
 
SPI Investor Deck October 2023
SPI Investor Deck October 2023SPI Investor Deck October 2023
SPI Investor Deck October 2023
 
BFRG Investor Deck September_v2
BFRG Investor Deck September_v2BFRG Investor Deck September_v2
BFRG Investor Deck September_v2
 
BFRG Investor Deck September
BFRG Investor Deck SeptemberBFRG Investor Deck September
BFRG Investor Deck September
 
BioVie Presentation September 2023
BioVie Presentation September 2023BioVie Presentation September 2023
BioVie Presentation September 2023
 
Lantern Pharma September 8, 2023
Lantern Pharma September 8, 2023Lantern Pharma September 8, 2023
Lantern Pharma September 8, 2023
 
GENE Investor Presentation Genetic Technologies August 2023
GENE Investor Presentation Genetic Technologies August 2023GENE Investor Presentation Genetic Technologies August 2023
GENE Investor Presentation Genetic Technologies August 2023
 
Splash Beverage Investor Presentation June 2023
Splash Beverage Investor Presentation June 2023Splash Beverage Investor Presentation June 2023
Splash Beverage Investor Presentation June 2023
 
SEBV Presentation
SEBV PresentationSEBV Presentation
SEBV Presentation
 

Recently uploaded

Basics of Anatomy- Language of Anatomy.pptx
Basics of Anatomy- Language of Anatomy.pptxBasics of Anatomy- Language of Anatomy.pptx
Basics of Anatomy- Language of Anatomy.pptxAyush Gupta
 
Hot Call Girl In Chandigarh 👅🥵 9053'900678 Call Girls Service In Chandigarh
Hot  Call Girl In Chandigarh 👅🥵 9053'900678 Call Girls Service In ChandigarhHot  Call Girl In Chandigarh 👅🥵 9053'900678 Call Girls Service In Chandigarh
Hot Call Girl In Chandigarh 👅🥵 9053'900678 Call Girls Service In ChandigarhVip call girls In Chandigarh
 
VIP Call Girls Sector 67 Gurgaon Just Call Me 9711199012
VIP Call Girls Sector 67 Gurgaon Just Call Me 9711199012VIP Call Girls Sector 67 Gurgaon Just Call Me 9711199012
VIP Call Girls Sector 67 Gurgaon Just Call Me 9711199012Call Girls Service Gurgaon
 
Call Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Hot Call Girl In Ludhiana 👅🥵 9053'900678 Call Girls Service In Ludhiana
Hot  Call Girl In Ludhiana 👅🥵 9053'900678 Call Girls Service In LudhianaHot  Call Girl In Ludhiana 👅🥵 9053'900678 Call Girls Service In Ludhiana
Hot Call Girl In Ludhiana 👅🥵 9053'900678 Call Girls Service In LudhianaRussian Call Girls in Ludhiana
 
Call Girl Price Amritsar ❤️🍑 9053900678 Call Girls in Amritsar Suman
Call Girl Price Amritsar ❤️🍑 9053900678 Call Girls in Amritsar SumanCall Girl Price Amritsar ❤️🍑 9053900678 Call Girls in Amritsar Suman
Call Girl Price Amritsar ❤️🍑 9053900678 Call Girls in Amritsar SumanCall Girls Service Chandigarh Ayushi
 
VIP Call Girl Sector 25 Gurgaon Just Call Me 9899900591
VIP Call Girl Sector 25 Gurgaon Just Call Me 9899900591VIP Call Girl Sector 25 Gurgaon Just Call Me 9899900591
VIP Call Girl Sector 25 Gurgaon Just Call Me 9899900591adityaroy0215
 
Udaipur Call Girls 📲 9999965857 Call Girl in Udaipur
Udaipur Call Girls 📲 9999965857 Call Girl in UdaipurUdaipur Call Girls 📲 9999965857 Call Girl in Udaipur
Udaipur Call Girls 📲 9999965857 Call Girl in Udaipurseemahedar019
 
Russian Call Girls Kota * 8250192130 Service starts from just ₹9999 ✅
Russian Call Girls Kota * 8250192130 Service starts from just ₹9999 ✅Russian Call Girls Kota * 8250192130 Service starts from just ₹9999 ✅
Russian Call Girls Kota * 8250192130 Service starts from just ₹9999 ✅gragmanisha42
 
pOOJA sexy Call Girls In Sector 49,9999965857 Young Female Escorts Service In...
pOOJA sexy Call Girls In Sector 49,9999965857 Young Female Escorts Service In...pOOJA sexy Call Girls In Sector 49,9999965857 Young Female Escorts Service In...
pOOJA sexy Call Girls In Sector 49,9999965857 Young Female Escorts Service In...Call Girls Noida
 
Krishnagiri call girls Tamil aunty 7877702510
Krishnagiri call girls Tamil aunty 7877702510Krishnagiri call girls Tamil aunty 7877702510
Krishnagiri call girls Tamil aunty 7877702510Vipesco
 
Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...
Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...
Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...Sheetaleventcompany
 
Jalandhar Female Call Girls Contact Number 9053900678 💚Jalandhar Female Call...
Jalandhar  Female Call Girls Contact Number 9053900678 💚Jalandhar Female Call...Jalandhar  Female Call Girls Contact Number 9053900678 💚Jalandhar Female Call...
Jalandhar Female Call Girls Contact Number 9053900678 💚Jalandhar Female Call...Call Girls Service Chandigarh Ayushi
 
VIP Call Girls Noida Jhanvi 9711199171 Best VIP Call Girls Near Me
VIP Call Girls Noida Jhanvi 9711199171 Best VIP Call Girls Near MeVIP Call Girls Noida Jhanvi 9711199171 Best VIP Call Girls Near Me
VIP Call Girls Noida Jhanvi 9711199171 Best VIP Call Girls Near Memriyagarg453
 
💚😋Kolkata Escort Service Call Girls, ₹5000 To 25K With AC💚😋
💚😋Kolkata Escort Service Call Girls, ₹5000 To 25K With AC💚😋💚😋Kolkata Escort Service Call Girls, ₹5000 To 25K With AC💚😋
💚😋Kolkata Escort Service Call Girls, ₹5000 To 25K With AC💚😋Sheetaleventcompany
 
Dehradun Call Girls Service 08854095900 Real Russian Girls Looking Models
Dehradun Call Girls Service 08854095900 Real Russian Girls Looking ModelsDehradun Call Girls Service 08854095900 Real Russian Girls Looking Models
Dehradun Call Girls Service 08854095900 Real Russian Girls Looking Modelsindiancallgirl4rent
 
VIP Call Girls Noida Sia 9711199171 High Class Call Girl Near Me
VIP Call Girls Noida Sia 9711199171 High Class Call Girl Near MeVIP Call Girls Noida Sia 9711199171 High Class Call Girl Near Me
VIP Call Girls Noida Sia 9711199171 High Class Call Girl Near Memriyagarg453
 
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...indiancallgirl4rent
 
❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR Call G...
❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR   Call G...❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR   Call G...
❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR Call G...Gfnyt.com
 
Enjoyment ★ 8854095900 Indian Call Girls In Dehradun 🍆🍌 By Dehradun Call Girl ★
Enjoyment ★ 8854095900 Indian Call Girls In Dehradun 🍆🍌 By Dehradun Call Girl ★Enjoyment ★ 8854095900 Indian Call Girls In Dehradun 🍆🍌 By Dehradun Call Girl ★
Enjoyment ★ 8854095900 Indian Call Girls In Dehradun 🍆🍌 By Dehradun Call Girl ★indiancallgirl4rent
 

Recently uploaded (20)

Basics of Anatomy- Language of Anatomy.pptx
Basics of Anatomy- Language of Anatomy.pptxBasics of Anatomy- Language of Anatomy.pptx
Basics of Anatomy- Language of Anatomy.pptx
 
Hot Call Girl In Chandigarh 👅🥵 9053'900678 Call Girls Service In Chandigarh
Hot  Call Girl In Chandigarh 👅🥵 9053'900678 Call Girls Service In ChandigarhHot  Call Girl In Chandigarh 👅🥵 9053'900678 Call Girls Service In Chandigarh
Hot Call Girl In Chandigarh 👅🥵 9053'900678 Call Girls Service In Chandigarh
 
VIP Call Girls Sector 67 Gurgaon Just Call Me 9711199012
VIP Call Girls Sector 67 Gurgaon Just Call Me 9711199012VIP Call Girls Sector 67 Gurgaon Just Call Me 9711199012
VIP Call Girls Sector 67 Gurgaon Just Call Me 9711199012
 
Call Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Hyderabad Just Call 9907093804 Top Class Call Girl Service Available
 
Hot Call Girl In Ludhiana 👅🥵 9053'900678 Call Girls Service In Ludhiana
Hot  Call Girl In Ludhiana 👅🥵 9053'900678 Call Girls Service In LudhianaHot  Call Girl In Ludhiana 👅🥵 9053'900678 Call Girls Service In Ludhiana
Hot Call Girl In Ludhiana 👅🥵 9053'900678 Call Girls Service In Ludhiana
 
Call Girl Price Amritsar ❤️🍑 9053900678 Call Girls in Amritsar Suman
Call Girl Price Amritsar ❤️🍑 9053900678 Call Girls in Amritsar SumanCall Girl Price Amritsar ❤️🍑 9053900678 Call Girls in Amritsar Suman
Call Girl Price Amritsar ❤️🍑 9053900678 Call Girls in Amritsar Suman
 
VIP Call Girl Sector 25 Gurgaon Just Call Me 9899900591
VIP Call Girl Sector 25 Gurgaon Just Call Me 9899900591VIP Call Girl Sector 25 Gurgaon Just Call Me 9899900591
VIP Call Girl Sector 25 Gurgaon Just Call Me 9899900591
 
Udaipur Call Girls 📲 9999965857 Call Girl in Udaipur
Udaipur Call Girls 📲 9999965857 Call Girl in UdaipurUdaipur Call Girls 📲 9999965857 Call Girl in Udaipur
Udaipur Call Girls 📲 9999965857 Call Girl in Udaipur
 
Russian Call Girls Kota * 8250192130 Service starts from just ₹9999 ✅
Russian Call Girls Kota * 8250192130 Service starts from just ₹9999 ✅Russian Call Girls Kota * 8250192130 Service starts from just ₹9999 ✅
Russian Call Girls Kota * 8250192130 Service starts from just ₹9999 ✅
 
pOOJA sexy Call Girls In Sector 49,9999965857 Young Female Escorts Service In...
pOOJA sexy Call Girls In Sector 49,9999965857 Young Female Escorts Service In...pOOJA sexy Call Girls In Sector 49,9999965857 Young Female Escorts Service In...
pOOJA sexy Call Girls In Sector 49,9999965857 Young Female Escorts Service In...
 
Krishnagiri call girls Tamil aunty 7877702510
Krishnagiri call girls Tamil aunty 7877702510Krishnagiri call girls Tamil aunty 7877702510
Krishnagiri call girls Tamil aunty 7877702510
 
Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...
Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...
Call Girl In Zirakpur ❤️♀️@ 9988299661 Zirakpur Call Girls Near Me ❤️♀️@ Sexy...
 
Jalandhar Female Call Girls Contact Number 9053900678 💚Jalandhar Female Call...
Jalandhar  Female Call Girls Contact Number 9053900678 💚Jalandhar Female Call...Jalandhar  Female Call Girls Contact Number 9053900678 💚Jalandhar Female Call...
Jalandhar Female Call Girls Contact Number 9053900678 💚Jalandhar Female Call...
 
VIP Call Girls Noida Jhanvi 9711199171 Best VIP Call Girls Near Me
VIP Call Girls Noida Jhanvi 9711199171 Best VIP Call Girls Near MeVIP Call Girls Noida Jhanvi 9711199171 Best VIP Call Girls Near Me
VIP Call Girls Noida Jhanvi 9711199171 Best VIP Call Girls Near Me
 
💚😋Kolkata Escort Service Call Girls, ₹5000 To 25K With AC💚😋
💚😋Kolkata Escort Service Call Girls, ₹5000 To 25K With AC💚😋💚😋Kolkata Escort Service Call Girls, ₹5000 To 25K With AC💚😋
💚😋Kolkata Escort Service Call Girls, ₹5000 To 25K With AC💚😋
 
Dehradun Call Girls Service 08854095900 Real Russian Girls Looking Models
Dehradun Call Girls Service 08854095900 Real Russian Girls Looking ModelsDehradun Call Girls Service 08854095900 Real Russian Girls Looking Models
Dehradun Call Girls Service 08854095900 Real Russian Girls Looking Models
 
VIP Call Girls Noida Sia 9711199171 High Class Call Girl Near Me
VIP Call Girls Noida Sia 9711199171 High Class Call Girl Near MeVIP Call Girls Noida Sia 9711199171 High Class Call Girl Near Me
VIP Call Girls Noida Sia 9711199171 High Class Call Girl Near Me
 
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...
(Sonam Bajaj) Call Girl in Jaipur- 09257276172 Escorts Service 50% Off with C...
 
❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR Call G...
❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR   Call G...❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR   Call G...
❤️♀️@ Jaipur Call Girls ❤️♀️@ Meghna Jaipur Call Girls Number CRTHNR Call G...
 
Enjoyment ★ 8854095900 Indian Call Girls In Dehradun 🍆🍌 By Dehradun Call Girl ★
Enjoyment ★ 8854095900 Indian Call Girls In Dehradun 🍆🍌 By Dehradun Call Girl ★Enjoyment ★ 8854095900 Indian Call Girls In Dehradun 🍆🍌 By Dehradun Call Girl ★
Enjoyment ★ 8854095900 Indian Call Girls In Dehradun 🍆🍌 By Dehradun Call Girl ★
 

Aridis Investor Presentation 2021

  • 1. 1 Innovative Therapeutics For Respiratory Health Investor Presentation 1Q-2021
  • 2. 2 Forward Looking Statement These forward-looking statements relate to future events or future financial performance of the Company. All such forward-looking statements involve risks and uncertainties and are not guaranties of future performance. An investment in the securities of Aridis is speculative in nature, involves a high degree of risk, and should not be made by an investor who cannot bear the economic risk of its investment for an indefinite period of time and who cannot afford the loss of its entire investment. These include many important factors that affect our ability to achieve our stated objectives including, but not limited to: * The timing of regulatory submissions; * Our ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; * Approvals for clinical trials may be delayed or withheld by regulatory agencies; * Pre-clinical and clinical studies will not be successful or confirm earlier results or meet expecta- tions or meet regulatory requirements or meet performance thresholds for commercial success; * The timing and costs of clinical trials, the timing and costs of other expenses; * Our ability to obtain funding from third parties; * Management and employee operations and execution risks; * Loss of key personnel; * Competition; * Market acceptance of products; * Intellectual property risks; * Assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; * The uncertainty of future financial results; * Risks associated with this offering; * Our ability to attract collaborators and partners; * Our reliance on third party organizations. We operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations. We have filed a registration statement (including a prospectus) with the Securities and Exchange Commission ("SEC") for the offering to which this communication relates. Before you invest, you should read the prospectus in the registration statement and other documents we have filed with the SEC for more complete information about us and this offering. You may get these documents for free by visiting EDGAR on the SEC web site at http://www.sec.gov. Alternatively, we, any underwriter, or any dealer participating in the offering will arrange to send you the prospectus if you request it from Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor, New York, NY 10022; email: prospectus@cantor.com. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
  • 3. 3 Targets IND Pre-Clinical Products Phase 2 Phase 1 Phase 3 Gram (+) Bacteria S. aureus a-toxin Pneumonia & Blood Stream Infections HAP/VAP Cystic Fibrosis COVID-19 Gram (-) Bacteria P. aeruginosa LPS O11 Gram (-) & (+) Iron Acquisition Systems COVID-19 AR-301 mAb (Salvecin) AR-101 mAb (Aerumab) AR-501 (Panaecin) AR-712 mAb AR-701 Bacteremia A. baumannii AR-401 mAb Product Pipeline Next Milestone Interim Futility data 2H2021 Phase 2/3 tbd Phase 2a data 2H2021 Phase 1/2 2H2021 IND 4Q2022 Gram (-) Bacteria RBD mAb
  • 5. 5 3 0 Months 6 9 12 15 18 21 24 27 TRADITIONAL: Discovery, Development, and Manufacturing APEX TM Discovery, Development, and Manuf. 12-15 months time saving Convalescent COVID-19 patient B-cell Selected Cloned CDRs or H&L of IgG’s APEX TM Nanoarrays B-cell repertoire screening B.R.E.A.T.H. TM CHO cell line CRISPR Guided Integration GMP Manufacturing λPEX Monoclonal Antibody Discovery and Production Platform Technology
  • 6. 6 Kyaw MH et al., 2015 BMC Health Serv Res. 15:241 Restrepo (2010) ICHE 31:509-515 Hospital Days 7.2 60 days 40 days 20 days $220,000 $110,000 Control Staph Pseudomonas Control Staph Pseudomonas 37.9 55.4 $33,851 $146,978 $213,104 In-Patient Costs ICU stay All Cause Mortality 1.1 day 6.9 days 14.8 days 3% 16% 20% 1.1 day 6.9 days 14.8 days 3% 16% 20% ~252,000 ICU patients US claims database (2018) n=201 n=394 Healthcare Burden: S. aureus and P. aeruginosa Bacteria Hospital 44.4% % 0 . 1 2 y c a m r a h P % 3 . 6 1 y r o t a r o b a L Respiratory Treatment (Mech. ventilation) 9.3% Radiology (+CT Scans) 3.3% % 9 . 1 y g o l o i d r a C Operating Room 1.4% Diagnostics (Blood ECG) 1.9% Pulmonary Diagnostic 0.4% % 3 . 0 c i d a e p o h t r O Survey of 30 cases (median)
  • 7. 7 Normal Alveolus PMN Macrophages α-toxins α-toxins Staphylococcus aureus Staphylococcus aureus Targets S. aureus α-Toxin Necrosis Alveolar air space Type 1 cells Interstitium Anti-toxin monoclonal antibody approach is a proven MOA, e.g. Anthrax mAb Raxibacumab (GSK-EBSI) S. Aureus mAb MEDI4893 (AZN) Intact Immune Cell Gram (+) bacteria: S. aureus mAb α-toxins attacking immune cell Red blood cells Neutrophils Macrophages, Monocytes Toxins 2013, 5(6), 1140-1166 T-cells Pneumoncytes Endothelial cells AR-301 Mechanism of Action: Host cells killed by α-toxins Commercialized Under development
  • 8. 8 Antibiotics-alone Adjunct therapy Standard of Care Standard of Care AR-301 Superiority Trial Design VS. With positive data, provides for value-based premium reimbursement Therapeutic Treatment in Acute Pneumonia Setting
  • 9. 9 Randomized, double-blind, placebo-controlled, single ascending dose of AR-301 31 sites across EU and U.S. SOC [antibiotics alone] + Placebo n=16 SOC + AR-301 (1 mg/kg ) n= 6 SOC + AR-301 (3 mg/kg) n= 8 SOC + AR-301 (10 mg/kg) n=10 SOC + AR-301 (20 mg/kg) n= 8 48 patients with HAP or VAP caused by S. aureus Safety and pharmacokinetics Data trend in favor of adjunctive treatment benefit Time to removal of ventilator (VAP patients) Microbiological cure Shorter time to eradication Days in ICU Design Patient Selection Groups Primary Endpoint Secondary Endpoint Hospitalization days All-cause mortality Clinical cure rate AR-301 Phase 2: Trial Recently Completed
  • 10. 10 Antibiotic Half Life 20 mg/kg (hours) Time since start of infusion 50% (half-life mark) Mean Plasma Concentration 24 48 72 96 120 144 168 0 ug/mL 200 ug/mL 400 ug/mL 600 ug/mL Adjunctive AR-301 treated groups were well antibiotics alone (placebo) group (n=48). Few adverse events (AEs) deemed related to AR-301 (2.8%). No serious adverse events (SAEs) related to AR-301. Deaths were deemed unrelated to AR-301 treatment (n=6). (plasma half-life of 23-31 days) AR-301 AR-301: Favorable Phase 2 Safety & PK Data
  • 11. 11 Probability of Receiving Mechanical Ventilation Days on Mechanical Ventilators +AR-301 Pooled (n=20) Antibiotics alone (n=5) 5 10 15 20 25 100% 80% 60% 40% 40% 50% improvement 20% Probability of Receiving Mechanical Ventilation 0 Francois, B. et al. 2018 Intensive Care Medicine. Aggregated AR-301 treated VAP groups exhibited lower probability of requiring mechanical ventilation vs. placebo. Phase 2
  • 12. 12 1-to-1 randomized, double-blind, placebo-controlled, single dose IV infusion Enrolling 240 patients with VAP caused by S. aureus across 125 sites in 20 countries (U.S., EU, Asia) Evaluating the potential of adjunctive AR-301 (20 mg/kg) to SOC antibiotics vs. antibiotics alone Primary endpoint of clinical cure rate at day 21 Interim futility analysis of 120 patients readout in 1H2022 Test of Clinical Cure Randomize & Treat infusion AR-301 at 20 mg/kg IV infusion n = 120 Day 21 n = 120 Broad spectrum antibiotics Broad spectrum antibiotics (ClinicalTrials.gov ID NCT03027609) AR-301 Phase 3: Trial Design in 2H2021 and final data
  • 13. 13 Powering Calculation and Assumptions n = 240 enrollment target over-powered to achieve superior clinical cure rate p<0.05 ** Rationale for 20% absolute clinical cure rate improvement setting Considered clinically meaningful to physicians Ph2a data showed trend toward improvements in shorter ventilation time & microbiological eradication (i.e. 2 of the 3 components of the primary endpoint) AR-301 Phase 3 Study Study Power 80% 90% 75% 75% 95% 95% 20% 20% n = 55 n = 69 n = 110 n = 138 Control (SOC)* AR-301 + SOC Absolute ** Evaluable per group Total Enrolled Primary Endpoint: Clinical Cure Rate
  • 14. 14 Sources Potential S. aureus HAP/VAP Patients by Market 395,000 Patients in the US, Japan, EU Gram (+) Staphylococcus aureus-Induced HAP/VAP Lifecycle opportunities include surgical site, skin/skin structure, UTI, and BSI infections due to S. aureus Estimated $6 billion annual healthcare cost burden attributable to S. aureus nosocomial pneumonia Breakdown of Strains 48% 52% 1 DR/Decision Resources, LLC. 2016; 2 Chastre J, and Fagon J-Y, Ventilator-associated pneumonia, State of the Art, Am J Respir Critical Care Med, 2002 (165): 867-903. 3 Warren DK, Outcome and Attributable Cost of VAP among ICU patients in a suburban medical center, Critical Care Med 2003;31(5):1312-7. MRSA MSSA 90,000 251,600 U.S.A. Japan 53,700 Europe $6 Billion Market for (AR-301): VAP, HAP
  • 15. 15 SOC antibiotics in HAP/VAP: Avycaz / ceftazidime/avibactam (AstraZeneca): $13,764 (14 days course) Vibativ/ Telavancin (Astellas): $8,841 (21 days course) Pneumonia caused by MRSA $1,000 AR-301 Product Contribution Key Assumptions First-line adjunctive treatment MRSA only HAP / VAP / HCAP 60% marketshare US / EU / Japan $10,500 per course $Million (Net of Expenses) $800 $600 $400 $200 $00 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 1st Phase 3 2nd Phase 3 BLA & Launch
  • 16. 16 AR-301 Pre-Emptive Treatment In S. Aureus Colonized Patients Also Show Evidence of Clinical Benefits At-risk (non-infected) Asymptomatic Lung colonized, High risk Asymptomatic Decreased risk of VAP 32% Decreased risk of VAP 47% (<65 yrs old) Full-on lung infection Ventilator-assoc. pneumonia Prophylactic AstraZeneca’s Suvratoxumab Pre-emptive Phase 2 Results (n=196)*: [data 1H2022] Phase 3 (n = 240) Treatment for Acute AR-301 Data: Proxy Data from AZN’s Suvratoxumab
  • 17. 17 AR-501: Novel Inhaled Non-Antibiotic Mechanism of Action Small Molecule Anti-infective Iron (Fe) is necessary for bacterial metabolic functions. AR-501 (gallium, Ga) replaces Fe AR-501 impairs mulitple bacterial functions Standard antibiotics inhibit single targets Ga Gallium
  • 18. 18 PARI eFlow nebulizer AR-501 Phase 1/2: Healthy & Cystic Fibrosis Patients Phase 1 Healthy Volunteers (1H-2019) Single Ascending Dose 6 mg 18 patients 6 patients 20 mg AR-501 Done AR-501 Placebo 18 patients 6 patients Placebo 40 mg 6 mg 20 mg 40 mg (1H-2020) Multiple Ascending Doses t = 0, 1, 2, 3, 4 weeks Done AR-501 30 patients 15 patients Placebo 6 mg 20 mg 40 mg (2H-2021) Multiple Ascending Doses t = 0, 1, 2 weeks Phase 2 Cystic Fibrosis Patients Primary Endpoint: Safety and PK Secondary Endpoints: Lung function of CF patients (changes in FEV1) Sputum bacteriology Data Readout: Phase 2a CF subjects in 2H2021 CF Foundation Funded Ph1 study results: AR-501 was well tolerated
  • 19. 19 Sputum concentration mg/mL 300 IV Inhaled (est.) 2 Gallium Gallium Placebo Placebo 1 10% 8% 6% 4% 2% 0% -2% -4% -6% 6 14 28 56 60 60 58 60 59 59 57 57 56 56 Day Days Days Days Days Patients Patients Patients Patients Patients Mean Relative Change from Baseline FEV (L) Intent to Treat Population CF Patients Inhaled Delivery A single IV dose of gallium resulted in statistical significant improvement in lung infection Data from University of Washington: Goss, C. et al. 2018 N. Am. Cystic Fibrosis Conference Abstract #307 (*estimate based on animal PK data) Safety & Efficacy of IV Gallium Demonstrated Proxy Data:
  • 20. 20 *UK, So. Africa, Brazil, Japan SARS-CoV-2 strains AR-712 two mAbs cocktail bind to COVID’s spike protein, blocking COVID & its variants* from being able to bind to the host cell. AR-712: Inhaled COVID-19 mAb Program Highly potent SARS-CoV-2 fully human mAbs from convalescent COVID-19 patients - Proprietary stable inhaled formulation designed for direct lung delivery - Therapeutically eradicated SARS-CoV-2 at ultra low dose (~0.05 mg/kg) in animal challenge model - Up to year-long protection (engineered for plasma half-life extension) - Engineered removal of antibody disease enhancement (ADE) risk AR-712 LLY (CoV555) REGN (10933/10987) >1,000x 2 - 6 mg (est) 700 to 7,500 mg 2,400 to 8,000 mg AR-712 in-human dosing is the lowest vs. all competitors* *Scaling to human dose based on animal SARS-CoV-2 challenge study. See https://www.biorxiv.org/content/10.1101/2020.10.14.339150v1
  • 21. 21 AR-712: Inhaled COVID-19 mAb Program Convenient self-dosing in-home Target Populations - Designed to lower the barrier to COVID-19 treatment in outpatients - Treatment mild to moderate COVID-19 non-hospitalized patients - Prophylaxis [elderly, high risk frontline workers, etc] Phase 1/2 in 2H21 Phase 3 data in 2022 https://www.biorxiv.org/content/10.1101/2020.10.14.339150v1.
  • 22. 22 AR-301 AR-101 AR-501 AR-712 Phase 3 Interim Futility Phase 2a Full Data Phase 2b Full Data Ph1/2 Phase 2/3 T.B.D. Phase 3 Full Data 2021 2022 Key Milestones Toxin Blocker Immune Modulation Cystic Fibrosis COVID-19 IND Enabling Ph3
  • 23. 23 Vu Truong CEO, Director (Formerly Medimmune, Aviron) Michael Nazak Chief Financial Officer (Formerly Coherus, intekrin) Steve Chamow VP, Development (Formerly Genentech, Abgenix) Hasan Jafri Chief Medical Officer (Formerly AstraZeneca/Medimmune) Elizabeth Leininger VP, Regulatory (Formerly FDA, Novartis) Mitch Rosner VP, Quality (Formerly Synthetic Gen., IDEC) Lynne Deans VP, Clinical Operations (Formerly Roche, Dermira) Senior Management
  • 24. 24 Eric Patzer, Ph.D. Director, Chairman (Co-Founder, Aridis) Robert Ruffolo, Ph.D., D.Sc. Director (Former President Wyeth/Pfizer) Craig Gibbs, Ph.D., M.B.A. Director (Commercial Gilead; Genentech) John Hamilton, M.B.A. Director (CFO, Depomed; BioMarin) Susan Windham-Bannister, Ph.D. Director (Assoc. Women in STEM, Mass. Life Sci. Ctr) Vu Truong, Ph.D. Director (CEO, Aridis) Board of Directors
  • 25. 25 Financial Information Condensed Consolidated Statement of Operations Three Months Ended 09/30/2020 ($ in 000’s) Total revenue $1,000 Research and development $4,161 General and administrative $1,631 Loss from operations $(5,792) Net loss $(5,786) Balance Sheet As of Sept. 30, 2020 Cash and cash equivalents (excludes ~$8.5m Oct. 2020) $6,212 Common stock: 100,000,000 shares authorized; 8,923,374 shares issued and outstanding as of September 30th, 2020 Analyst Coverage ($18 - $22 PT) - Cantor Fitzgerald (Louise Chen) - HC Wainwright (Vernon Bernadino) - ROTH Capital (Jonathan Aschoff) - Maxim Group (Jason MacCarthy) - Northland Securities (Carl Byrnes) - Laidlaw (Frank Brisebois)